In a prospective multicenter cohort of 297 patients, Ter Borg et al. demonstrated that stratifying patients according to the combination of bilirubin and albumin allows the identification at baseline of UDCA-treated PBC patients that are at low (both normal bilirubin and albumin), median (abnormal bilirubin or albumin), and high risk (abnormal bilirubin and albumin) of future clinical events [157]. This evidence concerns the gene ALB and primary biliary cholangitis.